Pancreatolithiasis and pancreatic carcinoma. Evaluation of pancreatic excretion test with 5,5-dimethyl-2,4-oxazolidinedione.
The pancreatic excretion test with a weak acid of 5, 5-dimethyl-2,4-oxazolidinedione (DMO) was performed concomitantly with the pancreozymin-secretin test in 28 patients with pancreatolithiasis, 14 patients with pancreatic carcinoma, and 67 healthy subjects. The DMO concentration and total output of duodenal content after secretin stimulation, when corrected to the simultaneously determined plasma DMO concentration, were significantly reduced in the patients. While the pancreozymin-secretin test was abnormal in 96% of patients with pancreatolithiasis and in 86% of those with pancreatic carcinoma, the pancreatic DMO excretion test gave abnormal results in 100% of the patients. This suggests that the new test may well become effective in detecting early stages of pancreatic disease including carcinoma and chronic pancreatitis.
D002137:Calculi / Q000175:diagnosis*; D002766:Cholecystokinin; D004114:Dimethadione / Q000378:metabolism*; D004386:Duodenum / Q000378:metabolism; D006801:Humans; D010080:Oxazoles / Q000378:metabolism*; D010182:Pancreatic Diseases / Q000175:diagnosis*; D010190:Pancreatic Neoplasms / Q000175:diagnosis*; D012633:Secretin; D014293:Trimethadione / Q000378:metabolism
D010080:Oxazoles; D012633:Secretin; D002766:Cholecystokinin; D004114:Dimethadione; D014293:Trimethadione